What You Should Know:

您应该知道：

– Qure.ai, a prominent global innovator in healthcare AI, has successfully closed a $65M in Series D funding round led by Lightspeed and 360 ONE Asset, with contributions from Merck Global Health Innovation Fund and Kae Capital. The round also included participation from existing investors, including Novo Holdings, HealthQuad, and TeamFund. .

–Qure.ai是医疗保健人工智能领域的杰出全球创新者，在默克全球健康创新基金和Kae Capital的资助下，成功完成了由Lightspeed和360 ONE Asset牵头的6500万美元的D轮融资。这轮谈判还包括现有投资者的参与，包括Novo Holdings、HealthQuad和TeamFund。。

– This substantial investment will accelerate the company’s expansion into the US market and other regions, boost investments in foundational AI models, and facilitate strategic acquisitions in the med-tech space.

–这笔巨额投资将加速公司向美国市场和其他地区的扩张，推动对基础人工智能模型的投资，并促进医学技术领域的战略收购。

Mission to Make Healthcare More Accessible

使医疗保健更容易获得的使命

Founded in 2016, Qure.ai is dedicated to making healthcare more accessible and equitable across the globe. The company has developed AI solutions that have positioned it as the world’s most deployed healthcare AI, with applications in over 90 countries and 3000+ sites. Qure.ai’s technology powers the efficient identification and management of critical diseases..

Qure.ai成立于2016年，致力于在全球范围内使医疗保健更加方便和公平。该公司开发了人工智能解决方案，将其定位为世界上部署最多的医疗保健人工智能，其应用程序遍布90多个国家和3000多个站点。。。

Regulatory Compliance and Global Presence

法规遵从性和全球影响力

Qure.ai’s products have received 18 FDA-cleared indications and are Class IIb certified per EU MDR regulations, ensuring the highest standards of safety and efficacy. The company is headquartered in Mumbai, with regional offices in New York, London, and Dubai, reflecting its global reach and commitment to making healthcare AI accessible worldwide..

Qure。ai的产品已获得18项FDA批准的适应症，并根据欧盟MDR法规获得IIb级认证，确保了最高的安全性和有效性标准。该公司总部位于孟买，在纽约、伦敦和迪拜设有区域办事处，反映了其全球影响力和致力于在全球范围内提供医疗保健AI服务。。

Future Expansion to Strategic Markets

未来拓展战略市场

With this new funding, Qure.ai will focus on expanding its presence in the US and other strategic markets. The company will also invest in developing foundational AI models that can be applied across various healthcare domains. Additionally, Qure.ai plans to pursue acquisitions of complementary med-tech companies to further enhance its product portfolio and capabilities..

有了这笔新资金，Qure.ai将专注于扩大其在美国和其他战略市场的影响力。。此外，Qure.ai计划收购互补的医学技术公司，以进一步增强其产品组合和能力。。

“Qure.ai has become a trusted medical imaging AI partner to hospitals and healthcare organizations around the world. Our work is helping to unlock clinical efficiencies and drive up the standard of care delivered to patients in the focus areas of TB, Lung Cancer and Stroke,” said Prashant Warier, Co-founder and CEO of Qure.ai.

Qure.ai联合创始人兼首席执行官Prashant Warier表示：“Qure.ai已成为世界各地医院和医疗保健组织值得信赖的医学成像ai合作伙伴。我们的工作有助于释放临床效率，提高结核病、肺癌和中风等重点领域患者的护理标准。”。

“AI helps to overcome healthcare bottlenecks, from imaging reporting backlogs and low screening uptakes to workforce resource constraints, not just in western societies like the US and Europe, but in developing nations too. We also collaborate with half of the top 20 Pharma and MedTech companies including AstraZeneca, Medtronic, and J&J, to accelerate early diagnosis and timely treatment of diseases.

“人工智能有助于克服医疗保健瓶颈，从成像报告积压和低筛查率到劳动力资源限制，不仅在美国和欧洲等西方社会，而且在发展中国家也是如此。我们还与阿斯利康、美敦力和强生等前20大制药和医疗技术公司中的一半合作，以加速疾病的早期诊断和及时治疗。

This Series D round is an exciting step forward in our journey and will propel us forward in our mission to reach a billion patients through our solutions.”.

这轮D系列赛是我们旅程中令人兴奋的一步，将推动我们通过我们的解决方案接触十亿患者的使命向前迈进。”。